ZA201806356B - 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists - Google Patents
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonistsInfo
- Publication number
- ZA201806356B ZA201806356B ZA2018/06356A ZA201806356A ZA201806356B ZA 201806356 B ZA201806356 B ZA 201806356B ZA 2018/06356 A ZA2018/06356 A ZA 2018/06356A ZA 201806356 A ZA201806356 A ZA 201806356A ZA 201806356 B ZA201806356 B ZA 201806356B
- Authority
- ZA
- South Africa
- Prior art keywords
- dihydropyrimidine
- carboxamides
- oxo
- hydroxy
- apj agonists
- Prior art date
Links
- RVVVQQNYGKCVMV-UHFFFAOYSA-N 4-hydroxy-6-oxo-1h-pyrimidine-5-carboxamide Chemical class NC(=O)C1=C(O)N=CNC1=O RVVVQQNYGKCVMV-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662312780P | 2016-03-24 | 2016-03-24 | |
| PCT/US2017/023801 WO2017165640A1 (en) | 2016-03-24 | 2017-03-23 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201806356B true ZA201806356B (en) | 2021-05-26 |
Family
ID=58464691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/06356A ZA201806356B (en) | 2016-03-24 | 2018-09-21 | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10106528B2 (https=) |
| EP (1) | EP3433247B1 (https=) |
| JP (1) | JP6716711B2 (https=) |
| KR (1) | KR102433280B1 (https=) |
| CN (1) | CN109195963B (https=) |
| AR (1) | AR107973A1 (https=) |
| AU (1) | AU2017238504B2 (https=) |
| BR (1) | BR112018068341A2 (https=) |
| CA (1) | CA3018346A1 (https=) |
| CL (1) | CL2018002671A1 (https=) |
| CO (1) | CO2018011105A2 (https=) |
| EA (1) | EA037162B1 (https=) |
| ES (1) | ES2895124T3 (https=) |
| IL (1) | IL261904B (https=) |
| MA (1) | MA43761A (https=) |
| MX (1) | MX379088B (https=) |
| MY (1) | MY189454A (https=) |
| SG (1) | SG11201808163WA (https=) |
| TW (1) | TWI744301B (https=) |
| UY (1) | UY37169A (https=) |
| WO (1) | WO2017165640A1 (https=) |
| ZA (1) | ZA201806356B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3303330T3 (pl) | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| EP3383860B1 (en) | 2015-12-04 | 2021-01-20 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| TW201725203A (zh) | 2015-12-16 | 2017-07-16 | 必治妥美雅史谷比公司 | 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 |
| SG11201808163WA (en) * | 2016-03-24 | 2018-10-30 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| US10508104B2 (en) | 2016-06-14 | 2019-12-17 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists |
| CN110072850B (zh) | 2016-10-14 | 2023-07-21 | 百时美施贵宝公司 | 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂 |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) * | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| CA2258949C (en) | 1996-07-01 | 2008-05-06 | Reddy-Cheminor, Inc. | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| CA2416248A1 (en) | 2000-07-18 | 2002-01-24 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| RU2004135554A (ru) | 2002-05-09 | 2006-01-20 | Цитокинетикс, Инк. (Us) | Пиримидиноны, композиции на их основе и способы их использования |
| EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
| WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| WO2007124397A2 (en) | 2006-04-21 | 2007-11-01 | Trustees Of Boston University | Ionic viscoelastics and viscoelastic salts |
| EP2079707B1 (de) | 2006-10-10 | 2014-12-03 | proionic GmbH & Co KG | Verfahren zur umsetzung von 1,3-hetero-aromatischen 2-carboxylaten mit wasser |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| TW200845994A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| US20110253929A1 (en) | 2008-12-22 | 2011-10-20 | Basf Se | Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors |
| EP2432776B1 (en) | 2009-05-21 | 2019-09-11 | Universite Laval | Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics |
| JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| KR20140039242A (ko) | 2011-05-31 | 2014-04-01 | 메르크 파텐트 게엠베하 | 전해질 제형 |
| EP2714698B1 (en) | 2011-05-31 | 2016-11-09 | Merck Patent GmbH | Compounds containing hydrido-tricyano-borate anions |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| DK3013813T3 (da) | 2013-06-27 | 2019-06-03 | Pfizer | Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| KR102339016B1 (ko) | 2013-11-29 | 2021-12-14 | 프로이오닉 게엠베하 | 마이크로파 조사에 의한 접착제 경화 방법 |
| US10570128B2 (en) * | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| MX387055B (es) | 2014-06-06 | 2025-03-19 | Res Triangle Inst | Agonistas del receptor de apelina (apj) y usos de los mismos. |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
| HUE050317T2 (hu) | 2015-05-20 | 2020-11-30 | Amgen Inc | APJ receptor triazol agonistái |
| PL3303330T3 (pl) * | 2015-06-03 | 2019-10-31 | Bristol Myers Squibb Co | Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| CA3001974A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
| EP3383860B1 (en) | 2015-12-04 | 2021-01-20 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| TW201725203A (zh) | 2015-12-16 | 2017-07-16 | 必治妥美雅史谷比公司 | 作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮 |
| SG11201808163WA (en) * | 2016-03-24 | 2018-10-30 | Bristol Myers Squibb Co | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| US10508104B2 (en) | 2016-06-14 | 2019-12-17 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists |
-
2017
- 2017-03-23 SG SG11201808163WA patent/SG11201808163WA/en unknown
- 2017-03-23 ES ES17715361T patent/ES2895124T3/es active Active
- 2017-03-23 BR BR112018068341A patent/BR112018068341A2/pt not_active Application Discontinuation
- 2017-03-23 JP JP2018549910A patent/JP6716711B2/ja active Active
- 2017-03-23 EA EA201892123A patent/EA037162B1/ru not_active IP Right Cessation
- 2017-03-23 EP EP17715361.6A patent/EP3433247B1/en active Active
- 2017-03-23 MX MX2018011194A patent/MX379088B/es unknown
- 2017-03-23 KR KR1020187030255A patent/KR102433280B1/ko active Active
- 2017-03-23 CN CN201780031787.XA patent/CN109195963B/zh active Active
- 2017-03-23 TW TW106109801A patent/TWI744301B/zh not_active IP Right Cessation
- 2017-03-23 AU AU2017238504A patent/AU2017238504B2/en not_active Ceased
- 2017-03-23 WO PCT/US2017/023801 patent/WO2017165640A1/en not_active Ceased
- 2017-03-23 AR ARP170100736A patent/AR107973A1/es not_active Application Discontinuation
- 2017-03-23 CA CA3018346A patent/CA3018346A1/en active Pending
- 2017-03-23 MY MYPI2018703358A patent/MY189454A/en unknown
- 2017-03-23 MA MA043761A patent/MA43761A/fr unknown
- 2017-03-24 US US15/468,230 patent/US10106528B2/en active Active
- 2017-03-24 UY UY0001037169A patent/UY37169A/es unknown
-
2018
- 2018-09-06 US US16/122,975 patent/US10590113B2/en active Active
- 2018-09-20 IL IL261904A patent/IL261904B/en active IP Right Grant
- 2018-09-21 ZA ZA2018/06356A patent/ZA201806356B/en unknown
- 2018-09-21 CL CL2018002671A patent/CL2018002671A1/es unknown
- 2018-10-17 CO CONC2018/0011105A patent/CO2018011105A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509319A (ja) | 2019-04-04 |
| EP3433247B1 (en) | 2021-09-08 |
| IL261904A (en) | 2018-10-31 |
| MA43761A (fr) | 2021-05-05 |
| UY37169A (es) | 2017-09-29 |
| WO2017165640A1 (en) | 2017-09-28 |
| US10590113B2 (en) | 2020-03-17 |
| SG11201808163WA (en) | 2018-10-30 |
| US10106528B2 (en) | 2018-10-23 |
| US20170275272A1 (en) | 2017-09-28 |
| MY189454A (en) | 2022-02-14 |
| CA3018346A1 (en) | 2017-09-28 |
| EA037162B1 (ru) | 2021-02-12 |
| MX2018011194A (es) | 2019-01-10 |
| BR112018068341A2 (pt) | 2019-01-15 |
| KR102433280B1 (ko) | 2022-08-17 |
| CN109195963B (zh) | 2021-04-23 |
| IL261904B (en) | 2020-09-30 |
| ES2895124T3 (es) | 2022-02-17 |
| CO2018011105A2 (es) | 2018-10-22 |
| AU2017238504B2 (en) | 2021-05-27 |
| TWI744301B (zh) | 2021-11-01 |
| US20190002441A1 (en) | 2019-01-03 |
| MX379088B (es) | 2025-03-10 |
| CL2018002671A1 (es) | 2019-01-25 |
| KR20180129836A (ko) | 2018-12-05 |
| JP6716711B2 (ja) | 2020-07-01 |
| CN109195963A (zh) | 2019-01-11 |
| EP3433247A1 (en) | 2019-01-30 |
| EA201892123A1 (ru) | 2019-02-28 |
| AR107973A1 (es) | 2018-07-04 |
| TW201736362A (zh) | 2017-10-16 |
| AU2017238504A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201806356B (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| ZA201802451B (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| ZA201807350B (en) | Novel compounds as gpr119 agonists | |
| ZA201800715B (en) | Muscarinic agonists | |
| SG11201607030PA (en) | Antibodies, uses & methods | |
| ZA201607573B (en) | Novel compositions, uses and methods for making them | |
| GB201513743D0 (en) | Muscarinic agonists | |
| SG11201704160XA (en) | Antibodies, uses & methods | |
| BR112016018071A2 (pt) | composição de larvicida. | |
| HRP20190097T1 (hr) | Moluskicidni pripravak | |
| HK40002893A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| HK1255164A1 (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| GB201500297D0 (en) | Agonists | |
| GB201521485D0 (en) | . | |
| GB201611093D0 (en) | . | |
| GB201400386D0 (en) | Agonists | |
| GB201420970D0 (en) | eGURE, egure, Egure | |
| HUP1400305A2 (en) | Tideke ...... | |
| GB201503899D0 (en) | Playat.me | |
| GB201503680D0 (en) | Whatyouwearing.com | |
| GB201417023D0 (en) | Bizyfy.com | |
| GB201518806D0 (en) | L.e.n.r. | |
| GB201400885D0 (en) | MagneticChess.com | |
| GB201413950D0 (en) | Antibodies, uses & methods | |
| GB201501738D0 (en) | S.o.s.i.c.h. |